116 results about "Tumour site" patented technology

The invention provides a macromolecule bonding adriamycin medicine, a nanometer capsule and a preparation method thereof. The bonding medicine is bonded by a block copolymer of poly ethylene glycol-polylactic acid and adriamycin. Firstly, the block copolymer of poly ethylene glycol-polylactic acid is acquired by ring-opening polymerization of aliphatic cyclic esters with poly ethylene glycol, solvent and catalyst being in existence; then a carboxyl end group is transformed by a hydroxyl-terminated; and then with a condensing agent being in existence, the carboxyl end group carries out amidation reaction with the adriamycin; thus acquiring the macromolecule adriamycin bonding medicine. The bonding medicine has amphiphilic property, thus being able to self assembly to prepare the nanometer capsule with a core-shell structure in the water solution. The adriamycin is wrapped inside the capsule to play a role of isolation and protection, which overcomes the deficiencies of short circulation time in vivo, large dosage and severe allergic reaction existing in the current adriamycin preparation. In addition, the nanometer particles are expected to congregate in the blood circulation through the so-called 'enhanced infiltration and retention effect', so as to improve the targeting action of the adriamycin on the tumor location.

The invention provides a photosensitive liposome with encapsulated water-soluble medicament, which is composed of temperature-sensitive phospholipid, cholesterol and long circulation material and hollow gold nanoparticle, wherein, the hollow gold nanoparticle has a characteristic absorption peak at the near infrared zone with the wavelength of 700-900 nm, and the particle size distribution of the hollow gold nanoparticle is in the range of 20-100 nm. According to the invention, a brand new photosensitive liposome is composed by wrapping water-soluble medicament and hollow gold nanoparticle with temperature-sensitive liposome. Under the extraneous near infrared light, the wrapped hollow gold nanoparticle generates a photo-thermal treatment effect, simultaneously, the photo-thermal effect controls a rapid site-specific delivery of medicament in a large amount from the photosensitive liposome, thereby blood vessels in the tumour part can be damaged or the tumor cells can be killed effectively with a chemical treatment effect of the medicamen. The drug loaded liposome of the present invention realizes synchronous photo-thermal and medicament molecule treatment effect, and the treatment effect of disease such as tumour is substantially improved, and the invention has clinic applicability and real treatment meaning.

The invention relates to a preparation method of meso-porous silicon nanoparticle with reducing / enzyme dual response and targeting property. The preparation method of the meso-porous silicon nanoparticle with the reducing / enzyme dual response and targeting property comprises the following steps: synthesizing a meso-porous silicon nanoparticle; modifying a disulfide bond on the surface of the meso-porous silicon nanoparticle by adopting a chemical method, and grafting the disulfide bond with hyaluronic acid as a targeting molecule; by taking carboxyl on the targeting molecule as a reaction site, modifying polyethylene glycol to the surface of the compound nanoparticle, thus improving biocompatibity of the nanoparticle, and connecting the hyaluronic acid molecule with the targeting effect to the surface of the nano particle, thus obtaining the meso-porous silicon nanoparticle diagnosis agent with medicinal response releasing and imaging functions. The prepared particle has good dispersity, is uniform in particle size and is easy to prepare, the prepared multifunctional diagnosis agent has good biocompatibility, medicine can be released in a tumour part in a responding manner, and diagnosis integration of the tumour can be realized.

The invention relates to an NRP-1 ligand polypeptide-polyethylene glycol-phosphatide compound, an active targeting liposome drug delivery system mediated thereby and a preparation method thereof. A carrier system comprises; a. phosphatide; b. cholesterol; c. methoxy polyethylene glycol-phosphatide compound; and d. polypeptide-polyethylene glycol-phosphatide compound containing an RPARPAR sequence. The above components are in a molar ratio of: a:b=5:1-1:5, a:c=1000:0.1-1000:100, and a:d=1000:0.1-1000:100. The system can carry out intravenous route drug administration and target the drug to a tumour position according to tumour EPR effect and RPARPAR mediation effect. The liposome drug delivery system can be applied to tumour diagnosis or targeting delivery of a treatment medicament.

The invention relates to an aptamer-based targeted delivery microRNA nanometer carrier as well as a preparation method and application thereof. A targeting molecule is a sulfydryl-modified MUC-1molecule, and can be combined with cancer-inhibiting microRNA-34a, so that a MicroRNA-nanodiamond-protamine complex (MNPs) becomes AMNPs with an active targeting function; through electrostatic interaction, a negatively-charged aptamer-microRNA (Apt-miR) chimera is adsorbed to a cationic protamine-nanodiamond carrier to form a trinary compound carrier. The therapeutic effect of a nanotransport system on a non-small cell lung cancer is researched; the Apt-miR chimera is low in immunogenicity; the modified MUC-1 aptamer has high chemical stability in vivo, and can be chemically synthesized easily; in order to improve the transfection efficiency, a protamine-modified nanodiamond material (NPs) is used for helping miRNA to increase accumulation in a tumor part through permeability and retention enhancing effects.

The invention discloses a medicament for treating neovascularization diseases. The medicament employs miRNA-132 and miRNA-155 as targets and two specific antagomirs, antagomir-132 and antagomir-155, as the basic components. The above two micronucleus acids are knocked down in a lesion at the same time, so as to inhibit excessive proliferation of new vessels to achieve therapeutic effect. To ensure the effective application of the drug, the invention adopts in vivo delivery vectors, such as a histidine-lysine polypeptide polymer HKP and a ligand targeted delivery nanoparticle system RGD-PEG-HKP, in order to improve the specificity and efficiency of medicament delivered into angiogenesis sites (eye or tumor).

A system and method for therapy and diagnosis of a human or animal. At least one coupling element for coupling of radiation couples radiation from at least a first radiation source to a tumour site and / or from said second radiation source to said site and / or from said site to a detector. The coupling elements are combinations of at least one translatory distributor, at least one rotary distributor, and at least one operation mode selector means for directing either said therapeutic radiation or said diagnostic radiation to said site through said at least one first radiation conductor. The system may be used for interactive interstitial photodynamic tumour therapy. The system and method according to the invention combines the advantages of purely mechanical and purely non-mechanical solutions in a new and synergetic way.

The invention belongs to the technical field of medicine and relates to a redox dual-sensitive-bond bridged small-molecular prodrug and its self-assembled nanoparticles. The redox dual-sensitive-bondbridged small-molecular prodrug is made by connecting an antitumor drug with a carbon chain containing an unsaturated bond and active hydroxyl group through a selenium bond or a sulfur bond. The antitumor drug is an anticancer drug containing active hydroxyl group or amino group, selected from taxane groups, nucleoside compounds, anthracycline compounds or camptothecin compounds; the carbon chaincontaining the unsaturated bond and active hydroxyl group is vitamin E, ethylene glycol dioleate, citronellol, oleyl alcohol, linoleny alcohol or linoleic alcohol. The selenium bond is a mono-seleniumbond or di-selenium bond; the sulfur bond is mono-sulfur bond or di-sulfur bond. The redox dual-sensitive-bond bridged small-molecular prodrug can be self-assembled into nanoparticles, arriving at high drug-loading capacity, good stability, low toxic and side effect, specific quick drug release to tumor sites, and improving antitumor activity.

The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and / or TAAs that are shared with the antigens present in patients' tumour. In each case, tumour cells are utilised as the starting point on the premise that only tumour cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate. The cell lines are lethally irradiated utilising gamma irradiation at 50–300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.

The invention relates to a charge reversal Pulullan derivative and a synthesis method and application thereof. The Pulullan derivative is composed of a Pulullan framework, a multi-amino modified group and a beta-carboxylic acid amide modified group, has remarkable liver / liver cancer targeting property, and can quickly respond to a faintly acid tumor microenvironment and a cell endosome / lysosome so as to achieve reversal from electronegativity to electropositivity. By modifying poly(beta-amino ester) (PBAE) / polylactic acid-polyglycolic acid copolymer (PLGA) composite nanoparticles with the Pulullan derivative, liver cancer targeted delivery of nanoparticles can be mediated efficiently, effective release of a carried drug at the tumor position is achieved, and the charge reversal Pulullan derivative is a liver / liver cancer targeted carrier material with excellent performance for drugs, genes and image contract agents and has broad application space.

A PLGA gemcitabine slow release microball is disclosed in the present invention belonging to pharmaceutical field. The PLGA gemcitabine slow release microball is prepared by supplementary polylactic acid-glycolic acid and raw material medicine gemcitabine with the weight ratio of 95 :5 to 35 :65. The present invention has the advantages that: preparing gemcitabine and polylactic acid-glycolic acid into slow release microball, directly sendint to tumor part by syringe to execute regional slow release chemotherapy, gemcitabine are released slowly, the tumor part has high medicine concentration, long duration, strong action intensity, big killing force to tumor cell, thereby can improve curative effect to tumor; medicine are centralized to act on local, whole body has little medicine amount, adverse response is minimal. After medicine are released, polylactic acid-glycolic acid start to degradate as lactic acid and glycolic acid, further degradate as carbon dioxide and water, no effect to human body.

The present invention relates to chemokine-mucin fusions linked to glycosylphosphatidylinositol (GPI)-anchors and their use as anti-cancer adjuvants and as agents in tissue regeneration and suppression of vascular damage. GPI-linked chemokines are incorporated in the surface membrane of tumour cells and effect a recruitment of cytotoxic immune cells to the tumour site following injection in vivo. Leukocytes, cytotoxic T-cells and NK cells target the chemokine-GPI-anchored tumour cells and modulate cell-mediated lysis of the tumour cells. The efficiency of GPI-anchoring and modulation of immune cells can be further enhanced by linking the chemokine to a mucin domain followed by the GPI-anchor. The GPI-anchored chemokines, with or without mucin domain, are remarkably useful for the inhibition of tumour growth, tissue regeneration, and suppression of acute vascular damage to allografts.

The invention provides a preparation method and application of a PH reversible controlled release meso-porous silicon nanometer drug delivery system. The PH reversible controlled release meso-porous silicon nanometer drug delivery system comprises meso-porous silicon nanoparticles and a compact polytannic acid layer, wherein the meso-porous silicon nanoparticles are loaded with drugs; and the compact polytannic acid layer is tightly wrapped on the surface of the meso-porous silicon nanoparticles so as to adjust and control specific release of the drugs at a tumour site. According to the preparation method and application of the PH reversible controlled release meso-porous silicon nanometer drug delivery system in the invention, the drugs are loaded by taking the meso-porous silicon nanoparticles as the carrier; tannic acid and a polyamine molecular cross-linking agent with amino at both ends perform spontaneous oxidation polymerization in an alkaline condition to form the polytannic acid layer, which is used as intelligent gating molecules wrapped on the surface of drug loaded meso-porous silicon; therefore, PH reversible responsive controlled release is realized; finally, by meansof Schiff base reaction or Michael addition reaction, a targeting agent with amino or sulfydryl is covalently crosslinked on the surface of the polytannic acid layer, so that specific targeted drug delivery on cancer cells is realized; the designed synthetic nanometer drug delivery system can effectively solve the problem that the traditional stimulus responsive drug delivery system is nearly irreversible; and thus, the secondary toxicity possibly due to the fact that a drug carrier has drug residues can be avoided.

A system and method for interactive therapy and diagnosis of a human or animal comprising at least one first radiation source for emission of a diagnostic radiation, at least one second radiation source for emission of a therapeutic radiation, and at least one radiation conductor adapted to conduct radiation to a tumour site at or in said human or animal. A non-mechanical operation mode selector directs the therapeutic radiation and / or the diagnostic radiation to the tumour site through the radiation conductors. The operation mode selector means is preferably a non-mechanical optical switch and / or an optical combiner. The system may be used for interactive interstitial photodynamic tumour therapy.

The invention discloses a radioactive particle automatic implanting device. The radioactive particle automatic implanting device includes a radioactive particle storage device, a radioactive particle implanting needle, a push rod, a driving cylinder and a main controller, wherein the radioactive particle storage device is internally provided with a radioactive particle storage cavity, and a radioactive particle delivery channel is formed in the bottom of the radioactive particle storage cavity; a radioactive particle implanting channel is horizontally formed in the lower end of the radioactive particle storage device, and a first end of the radioactive particle implanting channel is an implanting needle insertion end; a second end is a push rod insertion end, and a radioactive particle lead-in mouth is formed in the part, close to the implanting needle insertion end, of the inner top surface of the radioactive particle implanting channel; a radioactive particle slide path is arranged between the radioactive particle lead-in mouth and the bottom of the radioactive particle delivery channel, and the radioactive particle implanting needle is connected with the implanting needle insertion end; the front end of the push rod is inserted into the push rod insertion end, and the rear end is connected with the driving cylinder. The radioactive particle automatic implanting device has the advantages of automatically implanting large-batch radioactive particles into a tumor part of the body of a patient, and the use effect is good.

The present invention provides a method of potentiating radiation therapy for treatment of a cancer or tumor comprising administrating to a subject in need thereof a therapeutically effective amount of a radiosensitizer in combination of a radiation therapy to a locus of the cancer or tumor, wherein the radiosensitizer is an extract of Schisandra chinensis (Turcz.) Baill, or the active ingredient isolated therefrom, particularly Schisandrin B.

The invention relates to a preparation method of a targeted long-circulation nano-drug carrier for photo-thermal synergistic chemotherapy. The invention relates to a preparation method of a targeted long-circulation nano-drug carrier for photo-thermal synergistic chemotherapy. The preparation method comprises the following steps: (1) preparing mesoporous silica; (2) coating the mesoporous silica with polydopamine; (3) loading an anti-cancer drug; (4) modifying the erythrocyte membrane by adopting biotin; (5) wrapping the mesoporous silica loaded with the anti-cancer drug by using the biotin-modified erythrocyte membrane. According to the invention, local photo-thermal / chemotherapy synergistic treatment of cancer tissues is realized through the PDA coating, so the treatment efficiency is improved; through wrapping of the erythrocyte membrane, the synthesized nanoparticles can effectively avoid a biological barrier, blood circulation of the whole body is carried out, and efficient accumulation of the nanoparticles in tumors is realized; the active targeting is carried out by modifying biotin, so the aggregation of the drug carrier at a tumor part is further improved, the biocompatibility of the drug carrier is greatly improved, and the circulation time of the drug carrier in a human body is greatly prolonged.

A system and method for interactive interstitial photo-dynamic tumour therapy and / or photothermal tumour therapy of a human or animal, said system comprising at least one radiation distributor, which is arranged for distribution of optical radiation from at least one radiation source to a reaction site, or from the reaction site to at least one radiation sensor. The radiation distributor comprises at least one translatory displacement element being translatory movable relatively to another element. First ends of first radiation conductors are fixed to the first translatory displacement element and first ends of second radiation conductors are fixed to the other element, wherein the first and the second radiation conductors are connectable to each other in different constellations through translatory movement of the translatory displacement element and the other element relative each other in order to obtain different operation modes of said system.

The invention discloses a cabazitaxel phospholipid composition, a preparation method thereof and an application. The cabazitaxel phospholipid composition comprises a cabazitaxel lipid complex, phospholipid and cholesterol and solves the problems that drugs are unstable, preparation steps before clinical use are complicated, an existing lipid preparation has poor in vitro and vivo stability and the like, in vivo circulation time of the drugs is prolonged, the composition has a certain targeting function, the drugs are enriched on a tumor site, toxic and side effects are reduced, and bioavailability is greatly improved.

The invention provides a nano-particle for mediating cascade reaction, and a preparation method thereof. The nano-particle provided by the invention comprises a core particle and a wrapping layer wrapping the core particle; the core comprises a metal-organic framework MIL-100 and dihydroporphin e6 loaded on the metal-organic framework MIL-100; and the wrapping layer is a hyaluronic acid layer. Bymeans of the nano-particle in the invention, cascade reaction at a tumour site can be realized; synergistic combination therapy of chemical kinetics and optical dynamics is realized; and thus, the better therapeutic effect of tumour is achieved.

The invention discloses a pH-sensitive precursor cation nanometer liposome of a target tumour cell and a preparation method thereof. A product consists of a cation liposome and a hydrophilic layer of which the surface is combined through electrostatic force and is provided with negative charge and which is easy to dissolve in an acidic environment. After intravenous injection, the liposome is not fused with a cell of which the surface is provided with negative charge in blood, can be rapidly fused with the tumor cell after reaching a tumor part, and effectively releases medicament to kill the tumor cell. The liposome can effectively transport an antitumor medicament to the tumor cell, overcomes the disadvantages of the conventional liposome, improves the efficiency of the antitumor medicament of killing the tumor cell, and reduces the toxicity of the medicament.

The invention relates to the technical field of medical appliances and discloses an electric-pulse ablation device capable of cooperating with drug administration. The electric-pulse ablation device comprises an endoscopic tube and a drug administration ablation assembly, wherein the drug administration ablation assembly comprises an intervention catheter, and a tube fixing member is arranged at the front end of the endoscopic tube. The electric-pulse ablation device can be intervened into a body of a patient in a non-invasive or minimally-invasive manner, the intervention catheter can go deep into the body through a natural orifice of the human body directly by dint of the existing endoscopic working passage, and then, a tumor region is ablated by using electric pulses; medicated liquid injection operation can also be carried out through the intervention catheter, and the treatment effect on a tumor can be effectively improved due to combined use of an ablation technology and medicated liquid; and relative movement between a dilation body and electrodes can be driven through an electric push-and-pull mechanism, two groups of electrode tips pricked into tumor tissue can be far away from each other due to wedge-shaped lugs arranged on the electrodes, then, the ablation diameter is increased greatly, the applicability of electric-pulse ablation is improved, and the difficulty of ablation operation is simplified.

The invention relates to a preparation method of porphyrin-terminated nano-scale fluorescent polyrotaxane. The preparation method comprises the following steps: mixing pseudorotaxane, porphyrin, PyBOP, DMAP and a solvent (anhydrous DMF), putting the mixture into a shaking table, reacting at 2-8 DEG C for 12-24 hours, adding methanol after the reaction is finished to separate out a solid, washing the solid, dispersing the solid into DMSO, adding deionized water, separating out a light pink precipitate, washing, and freeze-drying to obtain the product. The invention also provides an antitumor drug prepared by using the nano-scale fluorescent polyrotaxane as a drug carrier. Experiments show that the nano-scale fluorescent polyrotaxane can trace drugs, improve the enrichment of the drugs at tumor sites and reduce the toxic and side effects of the drugs on organisms, thereby improving the treatment effect of the drugs on tumors.

The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and / or TAAs that are shared with the antigens present in patients' tumour. In each case, tumour cells are utilised as the starting point on the premise that only rumour cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.

The invention discloses a targeting drug delivery system capable of resisting drug-resistant tumor and a preparation method of the targeting drug delivery system. The targeting drug delivery system isa nano-micelle taking a polyethylenimine-alpha-tocopheryl succinate polymer as a drug delivery core and a quercetin-modified hyaluronic acid polymer as a shell. Experiments prove that the targeting drug delivery system has certain acid sensitivity, can be actively released in a tumor microenvironment, is quickly diluted by blood after entering blood, cannot cause severe hemolysis, has higher safety, is applicable to intravenous injection administration, can reverse drug resistance of drug-resistant tumor cells to a certain degree, can significantly improve sensitivity of drug-resistant tumorcells to chemotherapy drugs, can increase accumulation of chemotherapy drugs at tumor parts, can remarkably improve treatment effects of the chemotherapy drugs on drug-resistant tumor, has good tumortargeting functions and has no obvious toxic or side effects; and besides, the preparation is easy to realize, simple to operate and good in repeatability.

The invention relates to a chemical structure and a preparation method of a tumor imaging agent, and in particular relates to a single photon emission computed tomography (SPECT) technetium (99mTc)-labeled RGD polypeptide trimer medicine, namely 99mTc-4P-RGD3. The tumor imaging medicine is combined with an integrin alphavbeta3 in a ligand mode so as to achieve an application of imaging a tumor part. The preparation method comprises the following implementing steps: linking HYNIC-Osu to 4P-RGD3 so as to obtain a ligand HYNIC-4P-RGD3, and chelating the HYNIC in the ligand with 99mTc so as to obtain the 99mTc-4P-RGD3 tumor imaging agent. A research on animal in-vivo distribution and a tumor imaging step proves that the tumor imaging agent is relatively high in tumor uptake and lower in background uptake to normal organs in a whole body, and the definition of tumor image of the whole body is improved; a drug metabolism experimental step shows that the 99mTc-4P-RGD3, after metabolized in an animal body, can be still discharged out of the body in a prototype mode. The technetium-labeled integrin alphavbeta3 tumor imaging agent (99mTc-4P-RGD3) prepared by the technical means disclosed by the invention can be used for solving a problem of high background uptake of other technetium-labeled RGD medicines in animal body, so that the technetium-labeled RGD medicine is more suitable for the assessment of tumors in whole body.

The invention discloses a camptothecin and Arg-Gly-Asp (RGD) polypeptide conjugate as well as a preparation method and application thereof. The structure of the polypeptide coupled camptothecin drug includes the following three parts: A, an RGD targeting peptide; B, a linker; and C, anticancer drug camptothecin, wherein the RGD polypeptide and the camptothecin are connected by using succinic anhydride as a connecting arm; and the synthesized RGD-camptothecin polypeptide drug conjugate can deliver the camptothecin to tumor cells, tissue, tumor microenvironment and other tumor sites to achieve the purpose of improving the problem of solubility of the camptothecin, making the drug camptothecin have a targeted effect, reducing the toxic and side effects on normal cells and tissue, so as to achieve the specific anti-tumor purpose.

The invention discloses a camptothecin (CPT) predrug as well as a preparation method and application thereof. The CPT predrug takes vitamin B6 as a hydrophilic end and CPT as a hydrophobic end, and the two parts are connected through a disfulfide bond. The CPT predrug can realize self-assembly in water to form a pH / redox double-sensitive nano-drug delivery system, the nano-drug delivery system hascertain acid sensitivity and redox sensitivity, under the action of high-concentration glutathione in a tumor microenvironment, the disulfide bond can be broken quickly and release the CPT, the drugCPT can be delivered to a tumor part efficiently, and the safety and effectiveness of CPT drug delivery are expected to be further improved.

The invention relates to composite porous microspheres and a preparation method and application thereof. According to a composite porous microsphere preparation and a preparation method and application thereof, the composite porous microsphere preparation comprises the following components: chitosan and derivatives thereof, sulfonated chitosan oligosaccharide and sodium alginate. The prepared microspheres of the invention have the advantages of being easy to collect, adjustable in size and the like, and not only have a good swelling degree suitable for embolism, but also have high drug loading capacity; release of the drug loaded on the microspheres at a tumor part can be used for tumor treatment, so that the physical therapy effect on the tumor is further enhanced.

The invention relates to the field of biomedicine. More specifically, the present invention relates to an intestinal cancer peritoneal metastasis prediction model and a construction method thereof. The intestinal cancer peritoneal metastasis prediction model is as follows: Model=32.892 + 1.51 * CT_stage + 1.884*tumor location + 20.447*distant metastatic sites - 19.898*thickened greater omentum - 20.222*pelvic nodules, wherein the CT_stage is a T stage, the tumor location is a tumor site, the tumor location is a tumor site, the distant metastatic sites are used as far transfer parts, the thickened greater omentum is used for thickening the omentum majus, and the pelvic nodules are pelvic implant nodules. The intestinal cancer peritoneal metastasis prediction model is high in prediction accuracy and has high sensitivity and specificity.